Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 1
1952 3
1954 2
1955 5
1956 1
1957 1
1958 2
1959 2
1960 7
1961 3
1962 1
1963 1
1964 7
1965 4
1966 6
1967 5
1968 4
1969 3
1970 3
1971 7
1972 6
1973 9
1974 4
1975 6
1976 1
1977 6
1979 2
1980 5
1981 1
1982 2
1984 3
1985 2
1987 3
1988 3
1989 2
1990 5
1991 2
1992 11
1993 11
1994 4
1995 7
1996 1
1997 4
1998 6
1999 4
2000 4
2001 5
2002 3
2003 5
2004 5
2005 7
2006 5
2007 6
2008 10
2009 9
2010 14
2011 16
2012 9
2013 13
2014 14
2015 18
2016 12
2017 17
2018 15
2019 25
2020 25
2021 26
2022 28
2023 41
2024 36
2025 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

547 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide and exercise training in obesity.
Bagherzadeh-Rahmani B, Marzetti E, Karami E, Campbell BI, Fakourian A, Haghighi AH, Mousavi SH, Heinrich KM, Brazzi L, Jung F, Baker JS, Patel DI. Bagherzadeh-Rahmani B, et al. Among authors: heinrich km. Clin Hemorheol Microcirc. 2024;87(4):465-480. doi: 10.3233/CH-242134. Clin Hemorheol Microcirc. 2024. Retraction in: Clin Hemorheol Microcirc. 2025 Nov 23:13860291251390410. doi: 10.1177/13860291251390410. PMID: 38640145 Retracted. Clinical Trial.
Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II.
Schwarz K, Iolascon A, Verissimo F, Trede NS, Horsley W, Chen W, Paw BH, Hopfner KP, Holzmann K, Russo R, Esposito MR, Spano D, De Falco L, Heinrich K, Joggerst B, Rojewski MT, Perrotta S, Denecke J, Pannicke U, Delaunay J, Pepperkok R, Heimpel H. Schwarz K, et al. Among authors: heinrich k. Nat Genet. 2009 Aug;41(8):936-40. doi: 10.1038/ng.405. Epub 2009 Jun 28. Nat Genet. 2009. PMID: 19561605 Free article.
Quo vadis precision oncology?
Heinrich K, Westphalen CB. Heinrich K, et al. J Cancer Res Clin Oncol. 2023 Jan;149(1):3-4. doi: 10.1007/s00432-022-04478-0. Epub 2023 Jan 13. J Cancer Res Clin Oncol. 2023. PMID: 36637503 Free PMC article. No abstract available.
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
Stintzing S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, Kaiser F, Heinrich K, Modest DP, Hofheinz RD, Decker T, Gerger A, Angermeier S, Rumpold H, Dickhut A, Öhler L, Gruenberger B, Niedersuess-Beke D, Sandmann M, Winder T, Trojan J, Prager G, Held S, Kumbrink J, Schmiegel W, Baraniskin A, Heinemann V. Stintzing S, et al. Among authors: heinrich k. J Clin Oncol. 2025 Apr 20;43(12):1463-1473. doi: 10.1200/JCO.24.01174. Epub 2025 Feb 4. J Clin Oncol. 2025. PMID: 39903881 Clinical Trial.
[Management of toxicities from immunotherapy].
Heinrich K, von Bergwelt-Baildon M, Theurich S. Heinrich K, et al. Dtsch Med Wochenschr. 2021 Sep;146(17):1119-1128. doi: 10.1055/a-1303-8780. Epub 2021 Aug 26. Dtsch Med Wochenschr. 2021. PMID: 34448188 Review. German.
[Scandal drug politics].
Heinrich K. Heinrich K. Fortschr Neurol Psychiatr. 2002 Sep;70(9):452-4. doi: 10.1055/s-2002-33761. Fortschr Neurol Psychiatr. 2002. PMID: 12215917 German. No abstract available.
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Reinacher-Schick A, Kasper-Virchow S, Fischer von Weikersthal L, Krammer-Steiner B, Prager GW, Taieb J, Heinemann V. Stintzing S, et al. Among authors: heinrich k. J Clin Oncol. 2023 Sep 1;41(25):4143-4153. doi: 10.1200/JCO.22.01420. Epub 2023 Jun 23. J Clin Oncol. 2023. PMID: 37352476 Clinical Trial.
Effects of Acute Citrulline Malate Supplementation on CrossFit® Exercise Performance: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study.
Devrim-Lanpir A, Ihász F, Demcsik M, Horváth AC, Góczán P, Czepek P, Takács J, Kimble R, Zare R, Gunes FE, Knechtle B, Weiss K, Rosemann T, Heinrich KM. Devrim-Lanpir A, et al. Among authors: heinrich km. Nutrients. 2024 Sep 24;16(19):3235. doi: 10.3390/nu16193235. Nutrients. 2024. PMID: 39408204 Free PMC article. Clinical Trial.
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V. Holch JW, et al. Among authors: heinrich k. Eur J Cancer. 2025 May 2;220:115388. doi: 10.1016/j.ejca.2025.115388. Epub 2025 Mar 25. Eur J Cancer. 2025. PMID: 40179821 Free article. Clinical Trial.
547 results